Search clinical trials for: SSR149415

Total 4 results

Sanofi

Completed

An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder (LENA)

Depressive Disorder

Canada, Russian Federation, Bulgaria, Mexico, Argentina, Chile, Croatia
Sanofi

Completed

An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder

Depressive Disorder

United States
Sanofi

Completed

Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder (NAPA)

Major Depressive Disorder

United States
Sanofi

Completed

An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder

Anxiety Disorders

United States

3

Subscribe